glp 1 slimming & health GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity GLP-1 Natural

Usage is also high among adults with heart disease, at 26%

While these effects initially made GLP-1 seem a promising candidate for drug development, the earliest clinical studies from 1992 and 1993 revealed that GLP-1s half-life in the body was disappointingly short

In December 2025 the US Food and Drug Administration approved the first oral GLP-1 for weight management, oral semaglutide sold as the Wegovy pill, and on 1 April 2026 it approved Lillys orforglipron, marketed as Foundayo, the first GLP-1 tablet that can be taken at any time of day without food or water restrictions

Novel GLP-1 mimetics in diabetes: lixisenatide and albiglutide

While studying GLP-1s and how effectively they treat diabetes, researchers discovered how significantly these medications can also affect a persons appetite, satiety, and food intake